Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Exon 14 Skipping”

30 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 30 results

Testing effectiveness (Phase 2)Looking for participantsNCT03175224
What this trial is testing

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced CancerRenal Cancer+15 more
Apollomics Inc. 497
Not applicableStudy completedNCT06161051
What this trial is testing

Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States

Who this might be right for
Advanced Non-small Cell Lung Cancer and MET Exon 14 Skipping Mutation
Novartis Pharmaceuticals 287
Testing effectiveness (Phase 2)Study completedNCT04677595
What this trial is testing

Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Novartis Pharmaceuticals 36
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06762327
What this trial is testing

Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer

Who this might be right for
Solid Tumors
Nanjing First Hospital, Nanjing Medical University 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Testing effectiveness (Phase 2)Ended earlyNCT04926831
What this trial is testing

Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Novartis Pharmaceuticals 4
Not applicableLooking for participantsNCT05703516
What this trial is testing

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Who this might be right for
Non-Small-Cell Lung Carcinoma
Novartis Pharmaceuticals 44
Early research (Phase 1)Ended earlyNCT05435846
What this trial is testing

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer
Collin Blakely 3
Testing effectiveness (Phase 2)UnknownNCT04322578
What this trial is testing

Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital 120
Large-scale testing (Phase 3)Ended earlyNCT04427072
What this trial is testing

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 22
Testing effectiveness (Phase 2)WithdrawnNCT03240393
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
CarcinomaNon-Small-Cell Lung Cancer
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT02414139
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 373
Post-approval studies (Phase 4)Study completedNCT05110196
What this trial is testing

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Who this might be right for
Non-Small Cell Lung Carcinoma
Novartis Pharmaceuticals 50
Testing effectiveness (Phase 2)WithdrawnNCT03147976
What this trial is testing

QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors

Who this might be right for
Solid Tumor
NantPharma, LLC
Testing effectiveness (Phase 2)WithdrawnNCT04460729
What this trial is testing

A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases

Who this might be right for
Non-small Cell Lung Carcinoma (NSCLC)
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Looking for participantsNCT05800340
What this trial is testing

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Who this might be right for
Non-Small Cell Lung CancerRET Driver MutationBRAF V600 Mutation+3 more
Guangdong Provincial People's Hospital 30
Not applicableStudy completedNCT05675683
What this trial is testing

Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib

Who this might be right for
Metastatic Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 68
Early research (Phase 1)Active Not RecruitingNCT03993873
What this trial is testing

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorsMET Gene Alterations
Turning Point Therapeutics, Inc. 95
Early research (Phase 1)Study completedNCT00585195
What this trial is testing

Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Who this might be right for
Non-Small Cell Lung Cancer ALK-positiveNon-Small Cell Lung Cancer c-Met DependentNon-Small Cell Lung Cancer ROS Marker Positive+2 more
Pfizer 596
Testing effectiveness (Phase 2)UnknownNCT03693339
What this trial is testing

Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation

Who this might be right for
CancerLung Cancer MetastaticMET Gene Mutation
Asan Medical Center 27
Next Page